Opinion|Videos|August 22, 2024
Treating Relapsed/Refractory Follicular Lymphoma
The Oncology Brothers and Pallawi Torka, MD, review treatment options for patients with relapsed/refractory follicular lymphoma.
Advertisement
Advertisement
Related to this article
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
3
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
4
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
5